Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus cetuximab versus avelumab alone in recurrent/metastatic head and neck squamous cell carcinoma
2017-003592-64Phase 2Unknown
- Sponsor
- University College London
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Bavencio + Erbitux with Bavencio monotherapy (2 arms). Primary endpoint: Disease control rate at 24 weeks after randomisation. Status: unknown.
02
Drugs
avelumabcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-003592-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003592-64.